RaQualia Pharma Inc. (4579) AI Stock Analysis

• Market Cap: ¥20.28B
• Dividend Yield: N/A
• Average Volume (3M): 352.93K
• Price to Earnings (P/E): 87.6
• Beta (1Y): 0.91
• Revenue Growth: 9.87%
• EPS Growth: -24.41%
• Country: JP
• Employees: 64
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 35.82
• Shares Outstanding: 24,458,673
• 10 Day Avg. Volume: 795,170
• 30 Day Avg. Volume: 352,926
• PEG Ratio: -0.58
• Price to Book (P/B): 3.47
• Price to Sales (P/S): 6.01
• P/FCF Ratio: -56.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 48.4
• Revenue Forecast (FY): ¥4.59B

• Rating: 54 Neutral
• Price Target: ¥846.00 ▼(-16.24% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily constrained by fundamentals—most notably negative operating/free cash flow in 2025 and historically volatile earnings—despite a return to profitability and strong revenue growth. Technicals are supportive with an upward trend and positive momentum, but valuation is a meaningful headwind given the very high P/E and no dividend yield provided.

Positive Factors

Licensing-led business model

A licensing and collaboration model lets RaQualia monetize R&D via upfronts, milestones and royalties while shifting late‑stage costs and commercialization risk to partners. This durable model preserves capital, accelerates program de‑risking, and supports steady cashable value from pipeline assets over the medium term.

Negative Factors

Weak and inconsistent cash generation

Negative operating and free cash flow in 2025—after a history of uneven conversion—reduces internal funding capacity for clinical programs and increases reliance on partner deals or external capital. Persistently weak cash conversion raises financing and execution risk for a R&D‑heavy company over the medium term.

RaQualia Pharma Inc. Business Overview & Revenue Model

Company Description

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and ...

Read more

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and ...

How the Company Makes Money

RaQualia Pharma primarily generates revenue through (1) licensing and collaboration agreements for its drug candidates and related intellectual property, and (2) product-related income where it has commercialization rights. Under out-licensing/col...

Read more

RaQualia Pharma primarily generates revenue through (1) licensing and collaboration agreements for its drug candidates and related intellectual property, and (2) product-related income where it has commercialization rights. Under out-licensing/col...

RaQualia Pharma Inc. Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.98B	3.11B	1.90B	2.92B	2.78B
Gross Profit	3.27B	2.48B	1.66B	2.69B	2.46B
EBITDA	971.88M	188.27M	-111.80M	1.00B	1.02B
Net Income	273.12M	-495.03M	-323.66M	723.39M	755.79M
Balance Sheet
Total Assets	10.51B	9.66B	6.93B	6.26B	5.23B
Cash, Cash Equivalents and Short-Term Investments	3.24B	3.34B	3.76B	3.93B	2.66B
Total Debt	2.90B	3.45B	432.02M	222.34M	39.07M
Total Liabilities	3.62B	4.08B	809.83M	760.67M	446.19M
Stockholders Equity	6.90B	5.57B	6.12B	5.50B	4.79B
Cash Flow
Free Cash Flow	-423.98M	84.24M	-940.80M	1.45B	260.61M
Operating Cash Flow	-356.63M	180.94M	-718.60M	1.48B	366.03M
Investing Cash Flow	124.32M	-3.67B	-135.37M	-47.65M	-279.25M
Financing Cash Flow	380.26M	2.98B	793.45M	-29.56M	-16.44M

RaQualia Pharma Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1010.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4579, the sentiment is Neutral. The current price of 1010 is above the 20-day moving average (MA) of 862.25, above the 50-day MA of 963.88, and above the 200-day MA of 756.81, indicating a neutral trend. The MACD of -46.20 indicates Positive momentum. The RSI at 41.99 is Neutral, neither overbought nor oversold. The STOCH value of 43.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4579.

RaQualia Pharma Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4588	55 Neutral	¥68.40B	-20.18	―	―	-9.04%	13.09%
4579	54 Neutral	¥20.28B	87.60	―	―	9.87%	-24.41%
4565	52 Neutral	¥81.90B	-5.96	-19.31%	―	-1.96%	-64.18%
4571	52 Neutral	¥12.21B	-12.44	-26.70%	―	172.39%	8.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4563	47 Neutral	¥23.74B	-4.22	-184.71%	―	56.75%	-97.56%
4587	46 Neutral	¥155.34B	-57.13	-10.16%	―	-62.47%	-134.06%

RaQualia Pharma Inc. Corporate Events